Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

54.35 -2.24 (-3.96%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apogee Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Apogee Therapeutics to Participate in Upcoming Conferences
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million
From Apogee Therapeutics
Via GlobeNewswire
Why Apogee Therapeutics Stock Triumphed on Thursday
The company aims to raise gross proceeds of roughly $300 million in a new capital-raising effort. 
Via The Motley Fool
Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today
Via Stocktwits
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out
The small biotech company is looking to take on Regeneron and Sanofi's blockbuster, Dupixent. 
Via Investor's Business Daily
Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering
From Apogee Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
What's going on in today's after hours session
Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
Gold Falls 1%; ProKidney Shares Spike Higher
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Dow Dips 1%; Mustang Bio Shares Spike Higher
 
Via Benzinga
Topics Stocks
Let's uncover which stocks are experiencing notable gaps during today's session.
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot
Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot. 
Via Investor's Business Daily
What's going on in today's pre-market session
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
Top 2 Health Care Stocks That May Plunge This Month
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Apogee Therapeutics' Eczema Drug Provides Rapid Itch Relief In Phase 2 Trial
Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B is ongoing. 
Via Benzinga
Why Apogee Therapeutics Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
Webcast to be held Monday, July 7th at 8:00 a.m. ET 
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
From Apogee Therapeutics
Via GlobeNewswire
Why Is Apogee Therapeutics Stock Trading Higher On Monday?
Apogee's APG808 cut key asthma biomarker FeNO by 53% at 12 weeks with no severe adverse events, showing potential for long-term maintenance dosing. 
Via Benzinga
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
From Apogee Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.